Aug 11, 2025
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Aug 08, 2025
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Aug 08, 2025
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
Aug 05, 2025
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Jul 29, 2025
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
Jul 23, 2025
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
Jul 22, 2025
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
Jul 08, 2025
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Jun 11, 2025
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
May 23, 2025
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
May 14, 2025
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
May 06, 2025
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Apr 24, 2025
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
Apr 10, 2025
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
Apr 10, 2025
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Mar 07, 2025
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
Feb 25, 2025
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Feb 18, 2025
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Feb 07, 2025
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
Jan 22, 2025
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium